Chemotherapy for Leukemia (Post nr. 1243)

MARC-detaljer
000 -LEADER
fixed length control field 04381nam a22004335i 4500
001 - CONTROL NUMBER
control field 60617
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20200226102306.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 170418s2017 si | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9789811033322
-- 978-981-10-3332-2
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-981-10-3332-2
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (DE-He213)978-981-10-3332-2
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC254-282
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.994
Edition number 23
245 10 - TITLE STATEMENT
Title Chemotherapy for Leukemia
Medium [electronic resource] :
Remainder of title Novel Drugs and Treatment /
Statement of responsibility, etc. edited by Takanori Ueda.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Singapore :
Name of producer, publisher, distributor, manufacturer Springer Singapore :
-- Imprint: Springer,
Date of production, publication, distribution, manufacture, or copyright notice 2017.
300 ## - PHYSICAL DESCRIPTION
Extent VIII, 361 p. 82 illus., 51 illus. in color.
Other physical details online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type text file
Encoding format PDF
Source rda
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note 1 An Overview -- Part I Bcr-Abl Tyrosine Kinase Inhibitors (TKIs) -- 2 Imatinib: Basic Results -- 3 Imatinib: Clinical Pharmacology and Therapeutic Results -- 4 Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs -- Part II New Antibodies for Leukemia -- 5 Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results -- 6 Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results -- 7 Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 8 Blinatumomab for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 9 Mogamulizumab in Adult T-cell Leukemia/Lymphoma -- Part III Signaling inhibitors -- 10. FLT3 inhibitors -- Part IV Differentiating Agents -- 11 Retinoic Acid, All-Trans Retinoic Acid (ATRA) and Tamibarotene -- 12 The Molecular Basis of Arsenic Trioxide Treatment for Acute Promyelocytic Leukemia (APL) -- 13 Arsenic Trioxide: Clinical Pharmacology and Therapeutic Results -- Part V New Chemotherapeutic Agents Including Antimetabolite -- 14 Nelarabine -- 15 Forodesine -- 16 Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology -- 17 Clinical Use of Clofarabine for Adults and Children with Leukemia -- 18 Re-Emerging Antimetabolites with Novel Mechanism of Action with Respect to Epigenetic Regulation: Basic Aspects -- 19 Epigenetic Regulator, Re-Emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results -- Part VI Therapy Targeting Leukemic Stem Cells -- 20 Therapies Targeting Leukemic Stem Cells.
520 ## - SUMMARY, ETC.
Summary, etc. This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells. This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hematology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Oncology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Medicine & Public Health.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Oncology.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hematology.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Ueda, Takanori.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Printed edition:
International Standard Book Number 9789811033308
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1007/978-981-10-3332-2">http://dx.doi.org/10.1007/978-981-10-3332-2</a>
912 ## -
-- ZDB-2-SME

Inga exemplar finns tillgängliga.

Medicinska biblioteket, Karlskoga lasarett
Måndag och onsdag: 10.00-14.30, Lunchstängt 11.30-12.00.
Fredagar: 10.00-12.00.

Madelene Ribbing, bibliotekarie
Lena Mileraux, biblioteksassistent/administratör
0586-664 49
medbibl.kgalas@regionorebrolan.se




Medicinska biblioteket, Lindesbergs lasarett
Dörren till bibliotket är upplåst mellan 07-16:00 på vardagar.
Dörren i hisshallen är öppen måndag - tosdag 7.00 - 15.00. Fredagar stängt.

Bibliotekets bemanning:
Mån: självbetjäning
Tis, ons och tors: 10-15
Fre: självbetjäning

Madelene Ribbing, bibliotekarie
Telefon: 0581-853 11, 072-14 77 552
medbibl.lbglas@regionorebrolan.se